This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider.
Carol H. Wysham, MD: Hello. I’m Dr Carol Wysham. Welcome to season 3 of the Medscape InDiscussion Type 2 Diabetes podcast series. Today, we’ll discuss chronic kidney disease (CKD) in patients with type 2 diabetes, sodium-glucose cotransporter 2 (SGLT2) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, and how and when we choose which agents.
Let me introduce my guest, Dr Liana Billings. Dr Billings is the vice chair of research in the Department of Medicine, Endeavor Health, in NorthShore Hospitals. She is the director of Clinical and Genetics Research in Diabetes and Cardiometabolic…